WHO. Global tuberculosis control. Surveillance, planning, financing. WHO Report 2008. Geneva: WHO, 2008:1–304 (
http://www.who.int/tb/publica tions/ global_report/2008/download _centre/en/index.html
Breen RA, Miller RF, Gorsuch T, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006;61:791–4.
Google Scholar
Brodhun B, Altmann D, Haas W. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2006. Berlin: Robert-Koch-Institut, 2008.
Google Scholar
Chan HS, Sun AJ, Hoheisel GB. Bronchoscopic aspiration and bronchoalveolar lavage in the diagnosis of sputum smear-negative pulmonary tuberculosis. Lung 1990;168:215–20.
Google Scholar
Davies PDO. In: Davies PDO, ed. Clinical tuberculosis, 2nd edn. London: Chapman & Hall, 1998.
Google Scholar
Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (DZK). Richtlinien zur Chemotherapie der Tuberkulose des Erwachsenen und der Kinder. Pneumologie 2001;55:494–511.
Google Scholar
Ewig S, Schaberg T. In: Ewig S, Hrsg. Tuberkulose heute, 2. Aufl. Oberhaching-München: Dustri, 2007.
Google Scholar
Lange C, Schaberg T, Diel R, et al. Aktueller Stand der Tuberkulosediagnostik. Dtsch Med Wochenschr 2006;131:341–7.
Google Scholar
Schaberg T, Hauer B, Haas WH, et al. Latente tuberkulöse Infektion: Empfehlungen zur präventiven Therapie bei Erwachsenen in Deutschland. Pneumologie 2004;58:255–70.
Google Scholar
American Thoracic Society, Prevention. CfDCa. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:221–47.
Google Scholar
Brock I, Weldingh K, Lillebaek T, et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65–9.
Google Scholar
Vier H, Schaberg T, Gillissen A. XDR (extensive resistance)-Tuberkulose. Pneumologie 2007;61: 606–9.
Google Scholar
Vier H, Gillissen A. Tuberkulose, so wird der Verdacht zur Gewissheit, Tuberkulosetherapie. PneumoNews 2008;2:36–9, 41-4.
Google Scholar
Dahle UR, Eldholm V, Winje BA, et al. Impact of immigration on the molecular epidemiology of Mycobacterium tuberculosis in a low-incidence country. Am J Respir Crit Care Med 2007;176:930–5.
Google Scholar
Johnston VJ, Grant AD. Tuberculosis in travellers. Travel Med Infect Dis 2003;1:205–12.
Google Scholar
Driver CR, Valway SE, Morgan WM, et al. Transmission of Mycobacterium tuberculosis associated with air travel. JAMA 1994;272:1031–5.
Google Scholar
Kenyon TA, Valway SE, Ihle WW, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis during a long airplane flight. N Engl J Med 1996; 334:933–8.
Google Scholar
Whitlock G, Calder L, Perry H. A case of infectious tuberculosis on two long-haul aircraft flights: contact investigation. N Z Med J 2001;114: 353–5.
Google Scholar
Diel R, Rüsch-Gerdes S, Niemann S. Molecular epidemiology of tuberculosis among immigrants in Hamburg, Germany. J Clin Microbiol 2004;42:2952–60.
Google Scholar
Lillebaek T, Andersen AB, Bauer J, et al. Risk of Mycobacterium tuberculosis transmission in a low-incidence country due to immigration from highincidence areas. J Clin Microbiol 2001;39:855–61.
Google Scholar
Vogtmann M, Beer J, Tannapfel A, et al. Zur Differenzialdiagnostik und Therapie bei Husten, Fieber, Brustschmerz und einseitigem Pleuraerguss. Ärzte bl. Sachsen 2004;5:191–4.
Hoheisel G, Roth M, Chan CH, et al. Procoagulant activity of purified protein derivative-stimulated pleural effusion mononuclear cells in tuberculous pleurisy. Respiration 1997;64:152–8.
Google Scholar
Hoheisel G, Izbicki G, Roth M, et al. Compartmentalization of pro-inflammatory cytokines in tuberculous pleurisy. Respir Med 1998;92:14–7.
Google Scholar
Hoheisel G, Sack U, Hui DS, et al. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis. Tuberculosis (Edinb) 2001;81:203–9.
Google Scholar
Hoheisel G, Vogtmann M, Chan KS, et al. Pleuritis tuberculosa — therapeutische Wertigkeit wiederholter Pleurapunktionen. Pneumologie 2004;58: 23–7.
Google Scholar
Chan CH, Arnold M, Chan CY, et al. Clinical and pathological features of tuberculous pleural effusion and its long-term consequences. Respiration 1991; 58:171–5.
Google Scholar
Wilson R. In: Wilson R, ed. Tuberculosis, European Respiratory Monograph: European Respiratory Society Journals, 1997.
Konietzko N, Loddenkemper R. In: Konietzko N, Hrsg. Tuberkulose. Stuttgart - New York: Thieme, 1999.
Dheda K, Udwadia ZF, Huggett JF, et al. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med 2005;11:195–202.
Google Scholar
Hauer B, Loddenkemper R, Detjen A, et al. Interferon-gamma-Tests in der Tuberkulose -Diagnostik -aktueller Stand. Pneumologie 2006;60:29–44.
Google Scholar
Hoffmann H, Loytved G, Bodmer T. Interferon-γ-Release-Assays in der Tuberkulosediagnostik. Internist (Berl) 2007;48:497–506.
Google Scholar
Hernández-Garduño E, Cook V, Kunimoto D, et al. Transmission of tuberculosis from smear negative patients: a molecular epidemiology study. Thorax 2004;59:286–90.
Google Scholar
Hoheisel GB, Tabak L, Teschler H, et al. Bronchoalveolar lavage cytology and immunocytology in pulmonary tuberculosis. Am J Respir Crit Care Med 1994a;149:460–3.
Hoheisel G, Chan BK, Chan CH, et al. Endobronchial tuberculosis: diagnostic features and therapeutic outcome. Respir Med 1994b;88:593–7.
Hoheisel G, Zheng L, Teschler H, et al. Increased soluble CD14 levels in BAL fluid in pulmonary tuberculosis. Chest 1995;108:1614–6.
Google Scholar
Kalsdorf B, Strassburg A, Greinert U, et al. [Clinical features and diagnosis of tuberculosis.] Pneumologie 2008;62:284–94.
Google Scholar
Schoch OD, Rieder P, Tueller, C et al. Diagnostic yield of sputum, induced sputum, and bronchoscopy after radiologic tuberculosis screening. Am J Respir Crit Care Med 2007;175:80–6.
Google Scholar
Jafari C, Ernst M, Strassburg A, et al. Local immunodiagnosis of pulmonary tuberculosis by enzymelinked immunospot. Eur Respir J 2008;31:261–5.
Google Scholar
Hong Kong Chest Service/Tuberculosis Research Centre. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36–41.
Google Scholar
Diel R, Forssbohm M, Loytved G, et al. Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose. Pneumologie 2007;61:440–55.
Google Scholar
Elmer A, Kortsik CS, Pies U, et al. Intracutaneous tuberculin test using the Mendel-Mantoux technique. Tuberculin reactivity among inpatients in a pneumology department. Pneumologie 2000;54:425–30.
Google Scholar
Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis- burden country. JAMA 2005;293:2756–61.
Google Scholar
Pai M, Riley LW Jr, Colford JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761–76.
Google Scholar
Passanante MR, Gallagher CT. Preventive therapy for contacts of multidrug-resistant tuberculosis. A Delphi-survey. Chest 1994;106:431–4.
Google Scholar
Rothel JS, Andersen P. Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent? Expert Rev Anti Infect Ther 2005;3:981–93.
Google Scholar
Stevens JP, Daniel TM. Chemoprophylaxis of multidrug-resistant tuberculous infection in HlV-uninfected individuals using ciprofloxacin and pyrazinamide. Chest 1995;108:712–7.
Google Scholar
Burmann WJ, Reves RR. Hepatotoxicity from rifampin plus pyrazinamide. Am J Respir Crit Care Med 2001;164:1112–3.
Google Scholar
Centers for Disease Control and Prevention. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR 2003;52:1–77.
Centers for Disease Control and Prevention. Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampicin and pyrazinamide for treatment of latent tuberculosis infection. United States, 2003. MMWR 2003;52:735–9.
Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999;3:847–50.
Google Scholar
Grazcyk J, O’Brien RJ, Bek E, et al. Assessment of rifampin containing regimens for tuberculosis preventive therapy: preliminary results from a pilot study in Poland. Am Rev Respir Dis 1991;143:119.
Google Scholar
Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-infection. Lancet 1998;351:786–92.
Google Scholar
Winkler J, Müller U, Nenoff P, et al. Treatment of invasive pulmonary aspergillosis in neutropenic patients by additional bronchoscopic amphotericin B instillation. Respiration 2007;74:663–73.
Google Scholar
Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368: 1575–80.
Google Scholar
Markel H, Gostin LO, Fidler DP. Extensively drug-resistant tuberculosis: an isolation order, public health powers, and a global crisis. JAMA 2007;298: 83–6.
Google Scholar